IgA nephropathy is a very common kidney disease among all age groups. Global data shows IgA nephropathy is more common among Asian and Caucasian people. In the US, IgA nephropathy is more likely to happen in males as compared to females. IgA nephropathy is one of the major causes of glomerulonephritis in the world.
Within ten years of the onset of IgA nephropathy, 15% of the patients develop end-stage renal disease, and 25%–30% of people develop ESRD within 20 years of the onset of IgA nephropathy.
IgA nephropathy is a rare disease due to IgA accumulation in the kidneys. The deposits of IgA cause blood and proteins to leak into the urine.
Early medications might help; hence, the FDA has approved a new IgA nephropathy treatment that reduces protein leakage into the urine.
More About New IgA Nephropathy Treatment
Tarpeyo, the new IgA nephropathy treatment, is being developed to target the root cause of the disease. Tarpeyo, also known as Budesonide, reduces proteinuria in adults with IgA Nephropathy and is in danger of rapid progression. Tarpeyo became the first-ever drug approved by the FDA to treat IgA nephropathy.
Tarpeyo has gained accelerated approval as it effectively reduces the protein in the urine. There is no evidence that Tarpeyo slows the decline in kidney function in IgA nephropathy patients. Extended clinical trials will be held to find an answer to this question.
Findings from the new treatment Tarpeyo
Tarpeyo and a placebo were administered at random by the researchers. After nine months of observation, it was found that people who administered,
Are there any side effects associated with Tarpeyo?
Just like any other treatment, Breyna too has side effects!
No matter how minimal, one should know them!
So, please pay attention!
Tarpeyo showed a few side effects during the clinical study. The side effects associated with this new IgA nephropathy treatment are listed below:
- Increased blood pressure
- Swollen legs and hands
- Skin rashes and acne
- Weight gain
- Breathing difficulty
- Indigestion
- Fatigue
- Swelling in face
Who are not eligible for Tarpeyo?
This new IgA nephropathy treatment has some serious consequences if taken without proper knowledge.
Read the below-mentioned points carefully to know who should not take Tarpeyo.
- People who have severe sensitivity reactions like anaphylaxis should avoid Trapeyo.
- The adverse effects may be more likely in patients with moderate to severe liver impairment. Hence such people are advised not to take Tarpeyo.
- Tarpeyo is an immunosuppressant nephropathy treatment. Patients having untreated fungal, bacterial, viral, or parasitic infections should avoid Tarpeyo.
- People having glaucoma, cataract, or diabetes, or people with a family history of the former issues should consult a medical practitioner before taking Tarpeyo.
- Pregnant women or women wanting to conceive soon should not take Tarpeyo as it may harm the baby.
References:
https://www.healio.com/news/nephrology
https://www.pharmacypracticenews.com/
